+ Watch GNVC
on My Watchlist
A biopharmaceutical company, which develops novel gene-based therapeutic drugs and vaccines.
I have been doin some research on GenVec and from what I am seeing, GV is headed in the right direction. With the new addition of Doctor Mahmoud and Doctor Connor to the board of directors, I am feeling really confident in the management of this company. Even though TNFerade (GenVecs Pancreatic Cancer fighting machine) ,wich was saposed to be released as GV's staple product, failed Phase III testing (Due to only an 8% gain in patients life expectancy), GV still has huge potential to release something big. Do your research on their current projects and you wont be let down!
This company is doing things very well, good balance sheets and very strong income and dividend too!!
GENVEC offers a Dynamic pipeline:Product Programs includeTNFerade™ for Pancreatic Cancer -late stage trialTNFerade™ for Head and Neck Cancer Vaccines HIV Vaccine Malaria Vaccine Foot and Mouth Disease Hearing & Balance Loss -Partnership w/NovartisDo your DD, Genvec may have the key to the first FDA approved Gene Therapy for Cancer in TNFERADE!!
Must have something...
I have had GNVC since it was sub 80 cents. The reports are coming out in the near future on whether TNFerade will be the break out drug against solid/non vascular cancers. I believe Pancreatic cancer was chosen for the platform arrangement because of how quickly it moves. The indications for Head and Neck cancer as well as possible skin cancers and other solid tumors will likely result in a partnership. The other pipeline therapies they have, for things like Malaria and hearing loss will also likely keep them going for a while. They may need to make another offering shortly, but not if a partnership is announced.
In recent clincal trials, Genvec's leading drug TNFerade (TM) has received very encouraging results for head,neck & esophageal cancers. For more information, please go to the companys web site: www.genvec.com The target price of $20.00 could be met from one month to within three years.
Got in with real money at 1.75 based on what they have in the pipeline.
They are in third phase trials for their main product which had promising results last year. This year they got the FDA to allow them to change the wording of the goal of the trials from 12month survival rate to overall survival rate, which is much more in line with their initial results (which showed a 10 month survival increase if I remember correctly). This should allow their trials to be successful and streamline FDA approval.They also inked a deal with a UK company to mass produce the Adenovector that is their main product. This shows me that they are expecting approval for the pancreatic treatment and are getting everything ready to roll out the product.This same treatment is also being tested for other types of cancers.They also have contracts with government and world organizations for vaccines for malaria and AIDS, plus are developing a treatment for hearing and balance loss.I think that if (and I suspect it will) their first product for pancreatic cancer is approved and starts to sell, then the other cancer treatments will not be far behind. I bought this in the $3 range (I have lost 50%), but it is a long hold. I expect to start seeing a turn around towards the end of summer 08, with a large increase in the 1st quarter 09 based on when I believe approval and manufacturing will begin.
Long term pick here, the ups and downs over the short term are going to be the results of day traders looking to make a few cents a share on hundreds of thousands of shares. These guys look very promising and am consifdering purchasing the stock with LTBH in mind.
Well because I'm getting it so much cheaper than everyone else. And they are increasing cash flow.
I like the price and the market that GNVC is after.
Today's news of the ASCO conference caused a 30% drop in the GNVC stock price. I believe that the company will figure out why the trials were unsuccessful. Like Edison and his filaments, the "light" will come on for GenVec.
this stock will continue to rise. It has contracts with the Navy and other services that will bring in revenue look for this stock to take off
Went up too fast. Wait a few months until it consolidates down in the $2 range.
The Vaccines they are developing with the navy ie malira and the HIV will push this company.
Good product & management.
Good products in the pipeline. Wait and see.
Good business model, market niche and business practices. Joining a completive industry but with government ties. Products show positive results. Management is strong and not flipping.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions